(Q45094114)

9 December 2017

title

Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage (English)

1 reference

9 December 2017

Sheila A Doggrell

1

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

Expert Opinion on Therapeutic Targets

9 December 2017

published in

1 reference

9 December 2017

volume

8

1 reference

9 December 2017

issue

5

1 reference

9 December 2017

page(s)

491-493

1 reference

Coronary artery disease: Part 1. Epidemiology and diagnosis.

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Cytochrome P450: major player in reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Interaction of new sulfaphenazole derivatives with human liver cytochrome p450 2Cs: structural determinants required for selective recognition by CYP 2C9 and for inhibition of human CYP 2Cs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Role of cytochrome P-450 in reperfusion injury of the rabbit lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Cytochrome P450 2C is an EDHF synthase in coronary arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.5.491

21 January 2018

Identifiers

DOI

10.1517/14728222.8.5.491

1 reference

9 December 2017

1 reference